Novo Nordisk NVO announced that it has submitted a regulatory application to the European Medicines Agency (EMA) seeking ...

The move follows a dramatic breakup in June between Hims & Hers and Danish drug maker Novo Nordisk, which makes the brand name weight loss drug Wegovy. Novo Nordisk accused the Hims & Hers of ...

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Novo Nordisk seeks EMA approval for 7.2 mg Wegovy dose after trials show 21% weight loss in people with obesity and type 2 diabetes.

Novo Nordisk launches Wegovy in India, targets obesity treatment market, offers semaglutide-based weekly injection TOI Business Desk / TIMESOFINDIA.COM / Jun 24, 2025, 15:58 IST ...

Novo Nordisk announced in a news release Monday that it had pulled its semaglutide, Wegovy, from Hims & Hers, alleging it was selling compounded drugs as "personalized" versions to customers.

Danish pharmaceutical giant Novo Nordisk has officially launched its flagship obesity drug Wegovy (semaglutide) in India, announced Managing Director Vikrant Shrotriya on Tuesday. Wegovy is a ...

Danish pharmaceutical giant Novo Nordisk on Tuesday launched its highly anticipated weight-loss injection, Wegovy, in India, aiming to tap into the country’s growing demand for anti-obesity drugs. The ...

Novo Nordisk is preparing to launch Wegovy in India, where millions of people are battling obesity and demand for the weight-loss drug is expected to be massive. The drug will be launched in ...

Hims & Hers stock fell 35% after Novo Nordisk ended their partnership on Monday. Novo Nordisk stopped the deal because Hims sold a cheaper version of Wegovy. Hims' stock has fluctuated with ...